Clinical tests have seen that Rimonabant may help over-weight and obese people to lose fat. It was also seen that the drug could lessen the risk of heart disease and diabetes, and be of help to people who are aiming to stop smoking.

Throughout the Western world, obesity has become the chronic problem linked with increased risk issues of cardiovascular disorders. The obesity around the stomach region particularly heightens the risk of diabetes, heart attacks and untimely morbidity in some cases. Smokers are more prone to these dangers.

Rimonabant is the anorectic anti-obesity, CB1 Cannabinoid receptor antagonist drug. The the majority of vital key of its effect is diminution in craving foodstuffs. Developed by Sanofi-Aventis, Acomplia (rimonabant) is a selective CB1 endocannabinoid receptor antagonist indicated for the treatment of obesity. It works by stopping endogenous cannabinoid binding to neuronal CB1 receptors. Activation of these receptors by endogenous cannabinoids, such as anadamide, heightens appetite.

Consistent with the one-year statistics, the results illustrated that over-weight and obese people using rimonabant 20mg/d gained significant reductions in body fat, waist circumference (an indicator of abdominal obesity) and better lipid and glycaemic profiles compared with placebo recipients. Rimonabant also had a significant impact on metabolic CVD risk issues, greater than that expected by fat-loss alone.

For the majority of people Rimonabant only kept effective for fat-loss for up to about 34 weeks, though continuous use of the drug has been seen to maintain the fat-loss. After ending their use of Rimonabant, the majority of people regained the majority of of the fat they had lost.